While the potential of amino acid transport inhibitors is promising, there are several challenges and limitations:
1. Specificity: Ensuring that the inhibitors are highly specific to cancer cell transporters and do not significantly affect normal cells is a major challenge. 2. Resistance: Cancer cells may develop resistance to these inhibitors through various mechanisms, such as upregulating alternative transporters or metabolic pathways. 3. Delivery: Effective delivery of these inhibitors to the tumor site while maintaining stability and bioavailability is another hurdle that needs to be addressed.
